Cantor Fitzgerald’s new price target on CABA represents over 1,000% potential upside to the stock’s closing price on Thursday ...

Fintel reports that on October 31, 2025, Cantor Fitzgerald maintained coverage of Cabaletta Bio (NasdaqGS:CABA) with a ...

Cabaletta Bio Inc. (NASDAQ: CABA) is one of the best stocks under $3 to invest in. On October 27, Cabaletta Bio announced ...

All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key registrational inclusion criteria exceeded the registrational primary endpoint, demonstrating major TIS resp ...

Cabaletta Bio (CABA) has attracted fresh attention after presenting early data from its RESET-PV clinical trial at the ESGCT Congress. The company reported that its CAR T cell therapy, rese-cel, ...

Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA vaccine oversight. FDA lifts REMS for approved CAR-T therapies, easing hospital ...

Cabaletta Bio offers pioneering CAR T-cell therapy for autoimmune diseases, with recent data showing promising efficacy and manageable safety. CABA's lead candidate, rese-cel, has demonstrated ...

Cabaletta Bio, Inc.'s CD19-directed CAR T-cell therapy shows early promise in treating autoimmune diseases, despite limited patient numbers and follow-up time. Financially, Cabaletta Bio has enough ...

Cabaletta Bio (CABA) announced new and updated clinical data on CABA-201 demonstrating the potential to achieve drug-free, compelling clinical responses based on eight patients dosed across the ...